Mark R. Litzow, MD

Mark Litzow, MD, discusses the challenges of using immunotherapy for the treatment of acute lymphoblastic leukemia.

Mark R. Litzow, MD, discusses the findings from the ECOG-ACRIN E1910 trial which evaluated blinatumomab added to chemotherapy vs chemotherapy alone in B-cell precursor acute lymphoblastic leukemia.

Mark R. Litzow, MD, discusses the methods and design used in the ECOG-ACRIN E1910 trial.

Recent advancements have improved the way physicians treat acute lymphoblastic leukemia.

Mark R. Litzow, MD, discusses the purpose of a trial of blinatumomab for patients with newly diagnosed B-lineage acute lymphoblastic leukemia.

Mark R. Litzow, MD, discusses the talk he gave on initial treatment options for patients with acute lymphoblastic leukemia during the National Comprehensive Cancer Network 2022 Annual Congress: Hematologic Malignancies.

Mark R. Litzow, MD, chair, ECOG-ACRIN Leukemia Committee, professor of medicine, Division of Hematology, Mayo Clinic, discusses the role of transplant in patients with acute lymphoblastic leukemia (ALL).

Mark R. Litzow, MD, chair, ECOG-ACRIN Leukemia Committee, professor of medicine, Division of Hematology, Mayo Clinic, discusses ways of conducting minimal residual disease (MRD) assessments in patients with ALL.